{"gene":"NFATC2IP","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1996,"finding":"NIP45 (NFATC2IP) was identified as a nuclear protein that interacts with the Rel homology domain (RHD) of NF-ATp via yeast two-hybrid, and synergizes with NF-ATp and c-Maf to activate the IL-4 cytokine promoter; overexpression of NIP45 with NF-ATp and c-Maf in B lymphoma cells induced measurable endogenous IL-4 protein production.","method":"Yeast two-hybrid interaction trap; transient overexpression; IL-4 promoter reporter assay; endogenous IL-4 ELISA","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assay plus functional promoter activation and endogenous cytokine induction; foundational paper replicated in multiple subsequent studies","pmids":["8943202"],"is_preprint":false},{"year":2001,"finding":"TRAF2 represses IL-4 gene transcription through direct interaction with NIP45, opposing NIP45-mediated IL-4 promoter activation; providing NIP45, NFAT, and c-Maf to cells normally refractory to IL-4 production results in substantial IL-4 secretion.","method":"Co-immunoprecipitation; IL-4 promoter reporter assay; IL-4 secretion measurement","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with functional reporter assay, single lab, two orthogonal methods","pmids":["11435475"],"is_preprint":false},{"year":2005,"finding":"TRAF1 associates with a fraction of NIP45 in the cytoplasm and prevents its translocation to the nucleus, thereby limiting NIP45-dependent IL-4 gene transcription and Th2 responses.","method":"Co-immunoprecipitation; subcellular fractionation/nuclear localization assay; TRAF1 knockout T cell analysis; in vivo Th2 challenge model","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus nuclear localization assay with functional cytokine readout in KO cells, single lab","pmids":["16352630"],"is_preprint":false},{"year":2005,"finding":"NIP45 (and its yeast orthologs Rad60 and Esc2) is a member of the RENi family of proteins harboring two C-terminal SUMO-like domains (SLDs); sequence analysis indicates RENi proteins interact non-covalently with transcription factors, SMC proteins, and HDACs through their SUMO-like domains.","method":"Computational sequence analysis; literature synthesis of known interactions","journal":"BMC bioinformatics","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — computational/bioinformatic analysis only, no direct experimental validation of NIP45 mechanism in this paper","pmids":["15698469"],"is_preprint":false},{"year":2010,"finding":"NIP45-deficient T helper cells show profound defects in NFAT-regulated cytokine genes (including IL-4) without affecting NFAT activation or lineage-specific transcription-factor expression; NIP45 enhances assembly of PRMT1 and PRMT1-linked H4R3 methylation at the IL-4 promoter, acting as a molecular rheostat for type-2 immune response amplification.","method":"Targeted gene knockout in mice; ChIP assay; cytokine ELISA; parasite infection model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype plus ChIP demonstrating PRMT1 and H4R3me recruitment mechanism, replicated in vivo","pmids":["20133688"],"is_preprint":false},{"year":2010,"finding":"The crystal structure of the second SUMO-like domain (SLD2) of mouse NIP45 was determined in free form and in complex with the SUMO E2 enzyme Ubc9; NIP45 SLD2 binds Ubc9 in a manner almost identical to SUMO itself and thereby inhibits elongation of poly-SUMO chains in biochemical assays; SLD2 does not bind SIM-containing proteins (RNF4 or other SUMO-binding proteins).","method":"X-ray crystallography; in vitro Ubc9 binding assay; poly-SUMO chain elongation inhibition assay","journal":"Proteins","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure determination plus in vitro biochemical reconstitution with mutagenic and binding analyses","pmids":["20077568"],"is_preprint":false},{"year":2012,"finding":"NIP45 colocalizes with TRAF6 in the cytosol of osteoclast progenitor cells; RANKL stimulation induces NIP45 nuclear translocation and colocalization with NFATc2; NIP45 binds NFATc2 but not NFATc1 by co-immunoprecipitation; shRNA knockdown of NIP45 increases NFATc1, NFATc2, TRAF6, p-IκB-α, and NF-κB activity, and enhances RANKL-induced osteoclast differentiation and bone resorption.","method":"Confocal microscopy; co-immunoprecipitation; shRNA knockdown; NF-κB luciferase reporter; TRAP staining; bone resorption assay","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with localization and functional loss-of-function assays, multiple orthogonal methods, single lab","pmids":["22105856"],"is_preprint":false},{"year":2012,"finding":"Mouse NIP45 is diffusely distributed in the nucleus under standard conditions; proteasome inhibition (MG132) causes NIP45 to relocalize to PML nuclear domains together with SUMOylated proteins; the N-terminal region of NIP45 binds free SUMO-3 and SUMO-3 chains in vitro.","method":"Stable overexpression cell line; immunofluorescence/confocal microscopy; in vitro binding assay with SUMO-3","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization experiment with functional consequence (proteasome-dependent redistribution) plus in vitro binding, single lab, two methods","pmids":["23159618"],"is_preprint":false},{"year":2021,"finding":"TRPV6 activates NFATC2 by increasing NFATC2IP (NIP45) phosphorylation at Ser204, with CDK5 identified as a candidate kinase; activated NFATC2 then upregulates ADAMTS6 to promote breast cancer cell migration.","method":"Overexpression/knockdown of TRPV6; phospho-specific detection of NFATC2IP Ser204; NFATC2 transcriptional activity assay; ADAMTS6 expression measurement; migration assay","journal":"Cancer letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, CDK5 role proposed but not directly confirmed with kinase assay or mutagenesis; phosphorylation site detected by western but kinase identity not rigorously established","pmids":["34265397"],"is_preprint":false},{"year":2023,"finding":"Human NIP45/NFATC2IP mediates an interphase pathway for converting DNA catenanes into double-strand breaks (DSBs) that activate the G2 DNA-damage checkpoint, preventing cytokinesis failure and binucleation; NIP45 acts via its SUMO-like domains to promote SUMOylation of specific factors including the SLX4 multi-nuclease complex, which contributes to catenane conversion into DSBs; NIP45 and the BTRR-PICH pathway resolve toxic DNA catenanes through non-epistatic pathways.","method":"Genome-scale CRISPR-Cas9 screen; genetic epistasis analysis; cell biology assays (binucleation, chromosome bridge quantification); SUMO pathway perturbation; SUMOylation assays of SLX4","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-scale screen plus mechanistic follow-up with epistasis and SUMOylation assays; multiple orthogonal methods in a focused study","pmids":["37474739"],"is_preprint":false},{"year":2024,"finding":"NFATC2IP is required for SUMO-dependent genome integrity; cells lacking NFATC2IP accumulate mitotic chromosome bridges and micronuclei under SUMO E1 inhibition; NFATC2IP associates with nascent DNA (acting in interphase/postreplicative resolution); NFATC2IP interacts with the SMC5/6 complex via its first SUMO-like domain and with UBC9 (SUMO E2) via its second SUMO-like domain; AlphaFold-Multimer modeling suggests NFATC2IP positions and activates the UBC9-NSMCE2 (SUMO E3) complex associated with SMC5/6.","method":"Genome-scale CRISPR/Cas9 screen; NFATC2IP knockout cells; nascent DNA association assay (iPOND or equivalent); Co-immunoprecipitation with SMC5/6 and UBC9; AlphaFold-Multimer structural modeling; chromosome bridge/micronuclei quantification","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with SMC5/6 and UBC9, clean KO with defined phenotype, structural modeling, and genome-scale screen validation; multiple orthogonal methods","pmids":["38503515"],"is_preprint":false},{"year":2024,"finding":"NFATC2IP (Nfatc2ip) is necessary and sufficient for cardiac hypertrophy in neonatal rat cardiomyocytes; Nfatc2ip binds the core promoter of β-Mhc and enhances its transcriptional activity; miR-31-5p targets the 3'UTR of Nfatc2ip to inhibit this pathway.","method":"Luciferase reporter assay; ChIP-qPCR; miR-31-5p overexpression/inhibition; in vitro and in vivo cardiac hypertrophy models (AAC rat); co-localization of Nfatc2ip and β-Mhc","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR and luciferase assay directly demonstrating promoter binding and transcriptional activation, plus in vivo model, single lab","pmids":["38894694"],"is_preprint":false}],"current_model":"NFATC2IP (NIP45) is a nuclear, SUMO-like domain-containing protein that (1) interacts with NF-ATp/NFATc2 and co-activates IL-4 transcription in cooperation with c-Maf, with TRAF1 and TRAF2 restraining this activity by retaining NIP45 in the cytoplasm; (2) promotes PRMT1-dependent H4R3 methylation at the IL-4 promoter to amplify type-2 immune responses; (3) harbors tandem C-terminal SUMO-like domains, the second of which binds Ubc9 and inhibits poly-SUMO chain elongation; (4) mediates SUMO-dependent genome integrity by interacting with the SMC5/6 complex (via SLD1) and UBC9 (via SLD2) to position and activate the UBC9-NSMCE2 E3 ligase complex; (5) drives an interphase pathway that converts toxic DNA catenanes into DSBs via SLX4 SUMOylation, activating the G2 checkpoint to prevent mitotic failure; and (6) can bind the β-MHC promoter to drive cardiac hypertrophic gene expression."},"narrative":{"mechanistic_narrative":"NFATC2IP (NIP45) is a nuclear, SUMO-like domain (SLD)-containing protein with two distinct functional lives: as a transcriptional co-activator of NFAT-dependent cytokine genes in immune cells and as a SUMO-pathway scaffold that safeguards genome integrity [PMID:8943202, PMID:38503515]. In its immunological role, NIP45 binds the Rel homology domain of NF-ATp/NFATc2 and synergizes with c-Maf to drive transcription from the IL-4 promoter, sufficient to induce endogenous IL-4 production in cells otherwise refractory to it [PMID:8943202]. Loss of NIP45 selectively cripples NFAT-regulated cytokine genes without affecting NFAT activation, because NIP45 promotes assembly of PRMT1 and PRMT1-dependent H4R3 methylation at the IL-4 promoter, acting as a rheostat that amplifies type-2 immune responses [PMID:20133688]. This activity is restrained by TRAF-family proteins: TRAF1 retains a cytoplasmic pool of NIP45 to block its nuclear translocation, while TRAF2 directly binds NIP45 to repress IL-4 transcription [PMID:11435475, PMID:16352630]. Structurally, the C-terminal SLD2 binds the SUMO E2 enzyme Ubc9 in a manner nearly identical to SUMO itself and inhibits poly-SUMO chain elongation [PMID:20077568]. Through these SLDs, NFATC2IP supports SUMO-dependent genome maintenance, interacting with the SMC5/6 complex via SLD1 and with UBC9 via SLD2 to position and activate the UBC9-NSMCE2 SUMO E3 ligase; cells lacking NFATC2IP accumulate mitotic chromosome bridges and micronuclei under SUMO E1 inhibition [PMID:38503515]. In a related interphase pathway, NFATC2IP drives SUMOylation of the SLX4 nuclease complex to convert toxic DNA catenanes into double-strand breaks that activate the G2 checkpoint, preventing cytokinesis failure and binucleation [PMID:37474739]. Additional roles in osteoclast differentiation via NFATc2 and in cardiac hypertrophy through β-MHC promoter binding have been documented [PMID:22105856, PMID:38894694].","teleology":[{"year":1996,"claim":"Established NIP45 as a physical and functional partner of NFAT, answering how IL-4 cytokine transcription is co-activated beyond the NFAT factor itself.","evidence":"Yeast two-hybrid against the NF-ATp RHD plus IL-4 promoter reporter and endogenous IL-4 induction in B lymphoma cells","pmids":["8943202"],"confidence":"High","gaps":["Did not define the domain of NIP45 mediating co-activation","Mechanism of transcriptional amplification unresolved"]},{"year":2001,"claim":"Identified TRAF2 as a direct negative regulator, showing NIP45 activity is actively repressed rather than constitutive.","evidence":"Co-IP and IL-4 promoter reporter with secretion measurement","pmids":["11435475"],"confidence":"Medium","gaps":["TRAF2 binding interface on NIP45 not mapped","Single lab, no reciprocal in vivo validation"]},{"year":2005,"claim":"Explained how cytoplasmic sequestration limits NIP45 function, defining TRAF1 as a localization gatekeeper for Th2 responses.","evidence":"Co-IP, subcellular fractionation, TRAF1-knockout T cells, and in vivo Th2 challenge","pmids":["16352630"],"confidence":"Medium","gaps":["Signal triggering NIP45 release/translocation unknown","Relationship to TRAF2 repression not reconciled"]},{"year":2005,"claim":"Placed NIP45 in the RENi family with two C-terminal SUMO-like domains, foreshadowing a SUMO-pathway function distinct from transcription.","evidence":"Computational sequence analysis and literature synthesis","pmids":["15698469"],"confidence":"Low","gaps":["No direct experimental validation of NIP45 SLD function in this work","Predicted SMC/HDAC interactions untested here"]},{"year":2010,"claim":"Defined the molecular mechanism of immune co-activation, showing NIP45 recruits PRMT1 and drives H4R3 methylation at the IL-4 promoter.","evidence":"Targeted knockout mice, ChIP for PRMT1 and H4R3me, cytokine ELISA, and parasite infection model","pmids":["20133688"],"confidence":"High","gaps":["How NIP45 selects NFAT target loci unclear","Direct NIP45-PRMT1 contact not structurally defined"]},{"year":2010,"claim":"Provided the structural basis for SUMO-pathway engagement, showing SLD2 mimics SUMO to bind Ubc9 and limit poly-SUMO chain growth.","evidence":"X-ray crystallography of SLD2 alone and with Ubc9 plus in vitro poly-SUMO elongation assays","pmids":["20077568"],"confidence":"High","gaps":["Cellular consequence of chain-elongation inhibition not addressed here","Role of SLD1 not structurally examined"]},{"year":2012,"claim":"Extended NFAT co-activation to osteoclast biology, linking NIP45 to RANKL-induced NFATc2 nuclear partnership and bone resorption.","evidence":"Confocal colocalization, Co-IP (NFATc2 not NFATc1), shRNA knockdown, NF-κB reporter, TRAP staining, and resorption assay","pmids":["22105856"],"confidence":"Medium","gaps":["Selectivity for NFATc2 over NFATc1 mechanism unexplained","Single lab"]},{"year":2012,"claim":"Connected NIP45 localization to SUMO biology, showing proteasome stress redistributes it to PML bodies and that its N-terminus binds SUMO-3 chains.","evidence":"Stable overexpression, immunofluorescence under MG132, and in vitro SUMO-3 binding","pmids":["23159618"],"confidence":"Medium","gaps":["Functional role of PML relocalization unknown","N-terminal SUMO binding interface not mapped"]},{"year":2021,"claim":"Implicated NIP45 phosphorylation in NFAT activation downstream of TRPV6 in cancer cell migration.","evidence":"TRPV6 overexpression/knockdown, phospho-Ser204 detection, NFATC2 activity and ADAMTS6 readouts, migration assay","pmids":["34265397"],"confidence":"Low","gaps":["CDK5 as the kinase not confirmed by kinase assay or mutagenesis","Functional importance of Ser204 not tested by phospho-mutants"]},{"year":2023,"claim":"Revealed an unanticipated genome-integrity function, showing NIP45 converts DNA catenanes into checkpoint-activating DSBs via SLX4 SUMOylation.","evidence":"Genome-scale CRISPR screen, epistasis analysis, binucleation/bridge quantification, and SLX4 SUMOylation assays","pmids":["37474739"],"confidence":"High","gaps":["Substrate range of NIP45-directed SUMOylation beyond SLX4 incomplete","How catenane recognition is achieved unknown"]},{"year":2024,"claim":"Defined the molecular scaffold underlying genome maintenance, showing NFATC2IP bridges SMC5/6 (via SLD1) and UBC9 (via SLD2) to position the UBC9-NSMCE2 E3 ligase.","evidence":"Genome-scale screen, knockout cells with bridge/micronuclei phenotypes, nascent-DNA association, reciprocal Co-IP, and AlphaFold-Multimer modeling","pmids":["38503515"],"confidence":"High","gaps":["Direct enzymatic activation of NSMCE2 not biochemically reconstituted","Physiological SUMO substrates at replication forks not enumerated"]},{"year":2024,"claim":"Documented a cardiac transcriptional role, showing NFATC2IP binds the β-MHC promoter to drive hypertrophy under miR-31-5p control.","evidence":"Luciferase reporter, ChIP-qPCR, miR-31-5p modulation, and AAC rat hypertrophy model","pmids":["38894694"],"confidence":"Medium","gaps":["Whether promoter binding is direct or NFAT-mediated unresolved","Cofactor requirement at β-MHC promoter undefined"]},{"year":null,"claim":"How NIP45's two functional regimes — NFAT-dependent transcriptional co-activation and SLD-mediated SUMO-pathway scaffolding — are partitioned across cell types and conditions remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model connecting transcriptional and genome-integrity roles","Regulatory switch (localization, phosphorylation, partner availability) between the two functions unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,10]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,9]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,6]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,4]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[9,10]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[5,10]}],"complexes":["SMC5/6"],"partners":["NFATC2","MAF","TRAF1","TRAF2","PRMT1","UBC9","SLX4","TRAF6"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8NCF5","full_name":"NFATC2-interacting protein","aliases":["45 kDa NF-AT-interacting protein","45 kDa NFAT-interacting protein","Nuclear factor of activated T-cells, cytoplasmic 2-interacting protein"],"length_aa":419,"mass_kda":45.8,"function":"In T-helper 2 (Th2) cells, regulates the magnitude of NFAT-driven transcription of a specific subset of cytokine genes, including IL3, IL4, IL5 and IL13, but not IL2. Recruits PRMT1 to the IL4 promoter; this leads to enhancement of histone H4 'Arg-3'-methylation and facilitates subsequent histone acetylation at the IL4 locus, thus promotes robust cytokine expression (By similarity). Down-regulates formation of poly-SUMO chains by UBE2I/UBC9 (By similarity)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q8NCF5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/NFATC2IP","classification":"Common Essential","n_dependent_lines":343,"n_total_lines":1208,"dependency_fraction":0.28394039735099336},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NFATC2IP","total_profiled":1310},"omim":[{"mim_id":"614525","title":"NFATC2-INTERACTING PROTEIN; NFATC2IP","url":"https://www.omim.org/entry/614525"},{"mim_id":"613493","title":"IMMUNODEFICIENCY, COMMON VARIABLE, 3; CVID3","url":"https://www.omim.org/entry/613493"},{"mim_id":"107265","title":"CD19 ANTIGEN; CD19","url":"https://www.omim.org/entry/107265"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NFATC2IP"},"hgnc":{"alias_symbol":["FLJ14639","NIP45","RAD60","ESC2"],"prev_symbol":[]},"alphafold":{"accession":"Q8NCF5","domains":[{"cath_id":"3.10.20.90","chopping":"265-339","consensus_level":"high","plddt":91.5324,"start":265,"end":339},{"cath_id":"3.10.20.90","chopping":"344-419","consensus_level":"high","plddt":86.4643,"start":344,"end":419}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NCF5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NCF5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NCF5-F1-predicted_aligned_error_v6.png","plddt_mean":65.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NFATC2IP","jax_strain_url":"https://www.jax.org/strain/search?query=NFATC2IP"},"sequence":{"accession":"Q8NCF5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8NCF5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8NCF5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NCF5"}},"corpus_meta":[{"pmid":"8943202","id":"PMC_8943202","title":"NF-AT-Driven interleukin-4 transcription potentiated by NIP45.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8943202","citation_count":116,"is_preprint":false},{"pmid":"19158389","id":"PMC_19158389","title":"The Saccharomyces cerevisiae Esc2 and Smc5-6 proteins promote sister chromatid junction-mediated intra-S repair.","date":"2009","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/19158389","citation_count":92,"is_preprint":false},{"pmid":"12897162","id":"PMC_12897162","title":"Replication checkpoint kinase Cds1 regulates recombinational repair protein Rad60.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12897162","citation_count":77,"is_preprint":false},{"pmid":"23935535","id":"PMC_23935535","title":"Distinct SUMO ligases cooperate with Esc2 and Slx5 to suppress duplication-mediated genome rearrangements.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23935535","citation_count":72,"is_preprint":false},{"pmid":"20444977","id":"PMC_20444977","title":"The Smc5/6 complex and Esc2 influence multiple replication-associated recombination processes in Saccharomyces cerevisiae.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/20444977","citation_count":70,"is_preprint":false},{"pmid":"11971984","id":"PMC_11971984","title":"The Schizosaccharomyces pombe rad60 gene is essential for repairing double-strand DNA breaks spontaneously occurring during replication and induced by DNA-damaging agents.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11971984","citation_count":58,"is_preprint":false},{"pmid":"19158388","id":"PMC_19158388","title":"Esc2 and Sgs1 act in functionally distinct branches of the homologous recombination repair pathway in Saccharomyces cerevisiae.","date":"2009","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/19158388","citation_count":54,"is_preprint":false},{"pmid":"26443850","id":"PMC_26443850","title":"Local regulation of the Srs2 helicase by the SUMO-like domain protein Esc2 promotes recombination at sites of stalled replication.","date":"2015","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/26443850","citation_count":50,"is_preprint":false},{"pmid":"15698469","id":"PMC_15698469","title":"Proteins with two SUMO-like domains in chromatin-associated complexes: the RENi (Rad60-Esc2-NIP45) family.","date":"2005","source":"BMC bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/15698469","citation_count":48,"is_preprint":false},{"pmid":"30132869","id":"PMC_30132869","title":"LncRNA AK077216 promotes RANKL-induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30132869","citation_count":46,"is_preprint":false},{"pmid":"21408210","id":"PMC_21408210","title":"SUMO-targeted ubiquitin ligase, Rad60, and Nse2 SUMO ligase suppress spontaneous Top1-mediated DNA damage and genome instability.","date":"2011","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21408210","citation_count":44,"is_preprint":false},{"pmid":"16354704","id":"PMC_16354704","title":"Rhp51-dependent recombination intermediates that do not generate checkpoint signal are accumulated in Schizosaccharomyces pombe rad60 and smc5/6 mutants after release from replication arrest.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16354704","citation_count":44,"is_preprint":false},{"pmid":"34265397","id":"PMC_34265397","title":"Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34265397","citation_count":39,"is_preprint":false},{"pmid":"33184279","id":"PMC_33184279","title":"Mus81-Mms4 endonuclease is an Esc2-STUbL-Cullin8 mitotic substrate impacting on genome integrity.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33184279","citation_count":28,"is_preprint":false},{"pmid":"20077568","id":"PMC_20077568","title":"Structural basis for regulation of poly-SUMO chain by a SUMO-like domain of Nip45.","date":"2010","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/20077568","citation_count":28,"is_preprint":false},{"pmid":"16880212","id":"PMC_16880212","title":"SUMO-binding motifs mediate the Rad60-dependent response to replicative stress and self-association.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16880212","citation_count":27,"is_preprint":false},{"pmid":"16352630","id":"PMC_16352630","title":"TRAF1 regulates Th2 differentiation, allergic inflammation and nuclear localization of the Th2 transcription factor, NIP45.","date":"2005","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16352630","citation_count":27,"is_preprint":false},{"pmid":"29693310","id":"PMC_29693310","title":"Genetic, epigenetic and transcriptional variations at NFATC2IP locus with weight loss in response to diet interventions: The POUNDS Lost Trial.","date":"2018","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29693310","citation_count":26,"is_preprint":false},{"pmid":"11435475","id":"PMC_11435475","title":"Tumor necrosis factor receptor-associated factor (TRAF)2 represses the T helper cell type 2 response through interaction with NFAT-interacting protein (NIP45).","date":"2001","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11435475","citation_count":26,"is_preprint":false},{"pmid":"27694623","id":"PMC_27694623","title":"Esc2 promotes Mus81 complex-activity via its SUMO-like and DNA binding domains.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27694623","citation_count":23,"is_preprint":false},{"pmid":"20133688","id":"PMC_20133688","title":"NIP45 controls the magnitude of the type 2 T helper cell response.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20133688","citation_count":21,"is_preprint":false},{"pmid":"18757937","id":"PMC_18757937","title":"A SUMO-like domain protein, Esc2, is required for genome integrity and sister chromatid cohesion in Saccharomyces cerevisiae.","date":"2008","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18757937","citation_count":17,"is_preprint":false},{"pmid":"35901591","id":"PMC_35901591","title":"miR-301b-5p and its target gene nfatc2ip regulate inflammatory responses in the liver of rainbow trout (Oncorhynchus mykiss) under high temperature stress.","date":"2022","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/35901591","citation_count":12,"is_preprint":false},{"pmid":"33446573","id":"PMC_33446573","title":"Esc2 orchestrates substrate-specific sumoylation by acting as a SUMO E2 cofactor in genome maintenance.","date":"2021","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/33446573","citation_count":12,"is_preprint":false},{"pmid":"37474739","id":"PMC_37474739","title":"The SUMO-NIP45 pathway processes toxic DNA catenanes to prevent mitotic failure.","date":"2023","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37474739","citation_count":11,"is_preprint":false},{"pmid":"19755492","id":"PMC_19755492","title":"Schizosaccharomyces pombe Cds1Chk2 regulates homologous recombination at stalled replication forks through the phosphorylation of recombination protein Rad60.","date":"2009","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/19755492","citation_count":11,"is_preprint":false},{"pmid":"22105856","id":"PMC_22105856","title":"NIP45 negatively regulates RANK ligand induced osteoclast differentiation.","date":"2012","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22105856","citation_count":10,"is_preprint":false},{"pmid":"38503515","id":"PMC_38503515","title":"NFATC2IP is a mediator of SUMO-dependent genome integrity.","date":"2024","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/38503515","citation_count":9,"is_preprint":false},{"pmid":"30838410","id":"PMC_30838410","title":"Esc2 promotes telomere stability in response to DNA replication stress.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30838410","citation_count":8,"is_preprint":false},{"pmid":"33600463","id":"PMC_33600463","title":"Shared and distinct roles of Esc2 and Mms21 in suppressing genome rearrangements and regulating intracellular sumoylation.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33600463","citation_count":6,"is_preprint":false},{"pmid":"38894694","id":"PMC_38894694","title":"miR-31-5p suppresses myocardial hypertrophy by targeting Nfatc2ip.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38894694","citation_count":6,"is_preprint":false},{"pmid":"23159618","id":"PMC_23159618","title":"Establishment of a human cell line stably overexpressing mouse Nip45 and characterization of Nip45 subcellular localization.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23159618","citation_count":5,"is_preprint":false},{"pmid":"27601258","id":"PMC_27601258","title":"Transcription factor Reb1 is required for proper transcriptional start site usage at the divergently transcribed TFC6-ESC2 locus in Saccharomyces cerevisiae.","date":"2016","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/27601258","citation_count":5,"is_preprint":false},{"pmid":"20885950","id":"PMC_20885950","title":"Characterisation of the SUMO-like domains of Schizosaccharomyces pombe Rad60.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20885950","citation_count":3,"is_preprint":false},{"pmid":"41849995","id":"PMC_41849995","title":"Sgs1 and Esc2 suppress chromosome translocations induced by a replication fork barrier in Saccharomyces cerevisiae.","date":"2026","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/41849995","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18317,"output_tokens":3443,"usd":0.053298,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10909,"output_tokens":3935,"usd":0.07646,"stage2_stop_reason":"end_turn"},"total_usd":0.129758,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"NIP45 (NFATC2IP) was identified as a nuclear protein that interacts with the Rel homology domain (RHD) of NF-ATp via yeast two-hybrid, and synergizes with NF-ATp and c-Maf to activate the IL-4 cytokine promoter; overexpression of NIP45 with NF-ATp and c-Maf in B lymphoma cells induced measurable endogenous IL-4 protein production.\",\n      \"method\": \"Yeast two-hybrid interaction trap; transient overexpression; IL-4 promoter reporter assay; endogenous IL-4 ELISA\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assay plus functional promoter activation and endogenous cytokine induction; foundational paper replicated in multiple subsequent studies\",\n      \"pmids\": [\"8943202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TRAF2 represses IL-4 gene transcription through direct interaction with NIP45, opposing NIP45-mediated IL-4 promoter activation; providing NIP45, NFAT, and c-Maf to cells normally refractory to IL-4 production results in substantial IL-4 secretion.\",\n      \"method\": \"Co-immunoprecipitation; IL-4 promoter reporter assay; IL-4 secretion measurement\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with functional reporter assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"11435475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TRAF1 associates with a fraction of NIP45 in the cytoplasm and prevents its translocation to the nucleus, thereby limiting NIP45-dependent IL-4 gene transcription and Th2 responses.\",\n      \"method\": \"Co-immunoprecipitation; subcellular fractionation/nuclear localization assay; TRAF1 knockout T cell analysis; in vivo Th2 challenge model\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus nuclear localization assay with functional cytokine readout in KO cells, single lab\",\n      \"pmids\": [\"16352630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NIP45 (and its yeast orthologs Rad60 and Esc2) is a member of the RENi family of proteins harboring two C-terminal SUMO-like domains (SLDs); sequence analysis indicates RENi proteins interact non-covalently with transcription factors, SMC proteins, and HDACs through their SUMO-like domains.\",\n      \"method\": \"Computational sequence analysis; literature synthesis of known interactions\",\n      \"journal\": \"BMC bioinformatics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — computational/bioinformatic analysis only, no direct experimental validation of NIP45 mechanism in this paper\",\n      \"pmids\": [\"15698469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NIP45-deficient T helper cells show profound defects in NFAT-regulated cytokine genes (including IL-4) without affecting NFAT activation or lineage-specific transcription-factor expression; NIP45 enhances assembly of PRMT1 and PRMT1-linked H4R3 methylation at the IL-4 promoter, acting as a molecular rheostat for type-2 immune response amplification.\",\n      \"method\": \"Targeted gene knockout in mice; ChIP assay; cytokine ELISA; parasite infection model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype plus ChIP demonstrating PRMT1 and H4R3me recruitment mechanism, replicated in vivo\",\n      \"pmids\": [\"20133688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The crystal structure of the second SUMO-like domain (SLD2) of mouse NIP45 was determined in free form and in complex with the SUMO E2 enzyme Ubc9; NIP45 SLD2 binds Ubc9 in a manner almost identical to SUMO itself and thereby inhibits elongation of poly-SUMO chains in biochemical assays; SLD2 does not bind SIM-containing proteins (RNF4 or other SUMO-binding proteins).\",\n      \"method\": \"X-ray crystallography; in vitro Ubc9 binding assay; poly-SUMO chain elongation inhibition assay\",\n      \"journal\": \"Proteins\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure determination plus in vitro biochemical reconstitution with mutagenic and binding analyses\",\n      \"pmids\": [\"20077568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NIP45 colocalizes with TRAF6 in the cytosol of osteoclast progenitor cells; RANKL stimulation induces NIP45 nuclear translocation and colocalization with NFATc2; NIP45 binds NFATc2 but not NFATc1 by co-immunoprecipitation; shRNA knockdown of NIP45 increases NFATc1, NFATc2, TRAF6, p-IκB-α, and NF-κB activity, and enhances RANKL-induced osteoclast differentiation and bone resorption.\",\n      \"method\": \"Confocal microscopy; co-immunoprecipitation; shRNA knockdown; NF-κB luciferase reporter; TRAP staining; bone resorption assay\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with localization and functional loss-of-function assays, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"22105856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Mouse NIP45 is diffusely distributed in the nucleus under standard conditions; proteasome inhibition (MG132) causes NIP45 to relocalize to PML nuclear domains together with SUMOylated proteins; the N-terminal region of NIP45 binds free SUMO-3 and SUMO-3 chains in vitro.\",\n      \"method\": \"Stable overexpression cell line; immunofluorescence/confocal microscopy; in vitro binding assay with SUMO-3\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization experiment with functional consequence (proteasome-dependent redistribution) plus in vitro binding, single lab, two methods\",\n      \"pmids\": [\"23159618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRPV6 activates NFATC2 by increasing NFATC2IP (NIP45) phosphorylation at Ser204, with CDK5 identified as a candidate kinase; activated NFATC2 then upregulates ADAMTS6 to promote breast cancer cell migration.\",\n      \"method\": \"Overexpression/knockdown of TRPV6; phospho-specific detection of NFATC2IP Ser204; NFATC2 transcriptional activity assay; ADAMTS6 expression measurement; migration assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, CDK5 role proposed but not directly confirmed with kinase assay or mutagenesis; phosphorylation site detected by western but kinase identity not rigorously established\",\n      \"pmids\": [\"34265397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Human NIP45/NFATC2IP mediates an interphase pathway for converting DNA catenanes into double-strand breaks (DSBs) that activate the G2 DNA-damage checkpoint, preventing cytokinesis failure and binucleation; NIP45 acts via its SUMO-like domains to promote SUMOylation of specific factors including the SLX4 multi-nuclease complex, which contributes to catenane conversion into DSBs; NIP45 and the BTRR-PICH pathway resolve toxic DNA catenanes through non-epistatic pathways.\",\n      \"method\": \"Genome-scale CRISPR-Cas9 screen; genetic epistasis analysis; cell biology assays (binucleation, chromosome bridge quantification); SUMO pathway perturbation; SUMOylation assays of SLX4\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-scale screen plus mechanistic follow-up with epistasis and SUMOylation assays; multiple orthogonal methods in a focused study\",\n      \"pmids\": [\"37474739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NFATC2IP is required for SUMO-dependent genome integrity; cells lacking NFATC2IP accumulate mitotic chromosome bridges and micronuclei under SUMO E1 inhibition; NFATC2IP associates with nascent DNA (acting in interphase/postreplicative resolution); NFATC2IP interacts with the SMC5/6 complex via its first SUMO-like domain and with UBC9 (SUMO E2) via its second SUMO-like domain; AlphaFold-Multimer modeling suggests NFATC2IP positions and activates the UBC9-NSMCE2 (SUMO E3) complex associated with SMC5/6.\",\n      \"method\": \"Genome-scale CRISPR/Cas9 screen; NFATC2IP knockout cells; nascent DNA association assay (iPOND or equivalent); Co-immunoprecipitation with SMC5/6 and UBC9; AlphaFold-Multimer structural modeling; chromosome bridge/micronuclei quantification\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with SMC5/6 and UBC9, clean KO with defined phenotype, structural modeling, and genome-scale screen validation; multiple orthogonal methods\",\n      \"pmids\": [\"38503515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NFATC2IP (Nfatc2ip) is necessary and sufficient for cardiac hypertrophy in neonatal rat cardiomyocytes; Nfatc2ip binds the core promoter of β-Mhc and enhances its transcriptional activity; miR-31-5p targets the 3'UTR of Nfatc2ip to inhibit this pathway.\",\n      \"method\": \"Luciferase reporter assay; ChIP-qPCR; miR-31-5p overexpression/inhibition; in vitro and in vivo cardiac hypertrophy models (AAC rat); co-localization of Nfatc2ip and β-Mhc\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR and luciferase assay directly demonstrating promoter binding and transcriptional activation, plus in vivo model, single lab\",\n      \"pmids\": [\"38894694\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NFATC2IP (NIP45) is a nuclear, SUMO-like domain-containing protein that (1) interacts with NF-ATp/NFATc2 and co-activates IL-4 transcription in cooperation with c-Maf, with TRAF1 and TRAF2 restraining this activity by retaining NIP45 in the cytoplasm; (2) promotes PRMT1-dependent H4R3 methylation at the IL-4 promoter to amplify type-2 immune responses; (3) harbors tandem C-terminal SUMO-like domains, the second of which binds Ubc9 and inhibits poly-SUMO chain elongation; (4) mediates SUMO-dependent genome integrity by interacting with the SMC5/6 complex (via SLD1) and UBC9 (via SLD2) to position and activate the UBC9-NSMCE2 E3 ligase complex; (5) drives an interphase pathway that converts toxic DNA catenanes into DSBs via SLX4 SUMOylation, activating the G2 checkpoint to prevent mitotic failure; and (6) can bind the β-MHC promoter to drive cardiac hypertrophic gene expression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NFATC2IP (NIP45) is a nuclear, SUMO-like domain (SLD)-containing protein with two distinct functional lives: as a transcriptional co-activator of NFAT-dependent cytokine genes in immune cells and as a SUMO-pathway scaffold that safeguards genome integrity [#0, #10]. In its immunological role, NIP45 binds the Rel homology domain of NF-ATp/NFATc2 and synergizes with c-Maf to drive transcription from the IL-4 promoter, sufficient to induce endogenous IL-4 production in cells otherwise refractory to it [#0]. Loss of NIP45 selectively cripples NFAT-regulated cytokine genes without affecting NFAT activation, because NIP45 promotes assembly of PRMT1 and PRMT1-dependent H4R3 methylation at the IL-4 promoter, acting as a rheostat that amplifies type-2 immune responses [#4]. This activity is restrained by TRAF-family proteins: TRAF1 retains a cytoplasmic pool of NIP45 to block its nuclear translocation, while TRAF2 directly binds NIP45 to repress IL-4 transcription [#1, #2]. Structurally, the C-terminal SLD2 binds the SUMO E2 enzyme Ubc9 in a manner nearly identical to SUMO itself and inhibits poly-SUMO chain elongation [#5]. Through these SLDs, NFATC2IP supports SUMO-dependent genome maintenance, interacting with the SMC5/6 complex via SLD1 and with UBC9 via SLD2 to position and activate the UBC9-NSMCE2 SUMO E3 ligase; cells lacking NFATC2IP accumulate mitotic chromosome bridges and micronuclei under SUMO E1 inhibition [#10]. In a related interphase pathway, NFATC2IP drives SUMOylation of the SLX4 nuclease complex to convert toxic DNA catenanes into double-strand breaks that activate the G2 checkpoint, preventing cytokinesis failure and binucleation [#9]. Additional roles in osteoclast differentiation via NFATc2 and in cardiac hypertrophy through β-MHC promoter binding have been documented [#6, #11].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established NIP45 as a physical and functional partner of NFAT, answering how IL-4 cytokine transcription is co-activated beyond the NFAT factor itself.\",\n      \"evidence\": \"Yeast two-hybrid against the NF-ATp RHD plus IL-4 promoter reporter and endogenous IL-4 induction in B lymphoma cells\",\n      \"pmids\": [\"8943202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the domain of NIP45 mediating co-activation\", \"Mechanism of transcriptional amplification unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified TRAF2 as a direct negative regulator, showing NIP45 activity is actively repressed rather than constitutive.\",\n      \"evidence\": \"Co-IP and IL-4 promoter reporter with secretion measurement\",\n      \"pmids\": [\"11435475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TRAF2 binding interface on NIP45 not mapped\", \"Single lab, no reciprocal in vivo validation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Explained how cytoplasmic sequestration limits NIP45 function, defining TRAF1 as a localization gatekeeper for Th2 responses.\",\n      \"evidence\": \"Co-IP, subcellular fractionation, TRAF1-knockout T cells, and in vivo Th2 challenge\",\n      \"pmids\": [\"16352630\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signal triggering NIP45 release/translocation unknown\", \"Relationship to TRAF2 repression not reconciled\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed NIP45 in the RENi family with two C-terminal SUMO-like domains, foreshadowing a SUMO-pathway function distinct from transcription.\",\n      \"evidence\": \"Computational sequence analysis and literature synthesis\",\n      \"pmids\": [\"15698469\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct experimental validation of NIP45 SLD function in this work\", \"Predicted SMC/HDAC interactions untested here\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the molecular mechanism of immune co-activation, showing NIP45 recruits PRMT1 and drives H4R3 methylation at the IL-4 promoter.\",\n      \"evidence\": \"Targeted knockout mice, ChIP for PRMT1 and H4R3me, cytokine ELISA, and parasite infection model\",\n      \"pmids\": [\"20133688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NIP45 selects NFAT target loci unclear\", \"Direct NIP45-PRMT1 contact not structurally defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Provided the structural basis for SUMO-pathway engagement, showing SLD2 mimics SUMO to bind Ubc9 and limit poly-SUMO chain growth.\",\n      \"evidence\": \"X-ray crystallography of SLD2 alone and with Ubc9 plus in vitro poly-SUMO elongation assays\",\n      \"pmids\": [\"20077568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequence of chain-elongation inhibition not addressed here\", \"Role of SLD1 not structurally examined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended NFAT co-activation to osteoclast biology, linking NIP45 to RANKL-induced NFATc2 nuclear partnership and bone resorption.\",\n      \"evidence\": \"Confocal colocalization, Co-IP (NFATc2 not NFATc1), shRNA knockdown, NF-κB reporter, TRAP staining, and resorption assay\",\n      \"pmids\": [\"22105856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Selectivity for NFATc2 over NFATc1 mechanism unexplained\", \"Single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected NIP45 localization to SUMO biology, showing proteasome stress redistributes it to PML bodies and that its N-terminus binds SUMO-3 chains.\",\n      \"evidence\": \"Stable overexpression, immunofluorescence under MG132, and in vitro SUMO-3 binding\",\n      \"pmids\": [\"23159618\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of PML relocalization unknown\", \"N-terminal SUMO binding interface not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Implicated NIP45 phosphorylation in NFAT activation downstream of TRPV6 in cancer cell migration.\",\n      \"evidence\": \"TRPV6 overexpression/knockdown, phospho-Ser204 detection, NFATC2 activity and ADAMTS6 readouts, migration assay\",\n      \"pmids\": [\"34265397\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"CDK5 as the kinase not confirmed by kinase assay or mutagenesis\", \"Functional importance of Ser204 not tested by phospho-mutants\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed an unanticipated genome-integrity function, showing NIP45 converts DNA catenanes into checkpoint-activating DSBs via SLX4 SUMOylation.\",\n      \"evidence\": \"Genome-scale CRISPR screen, epistasis analysis, binucleation/bridge quantification, and SLX4 SUMOylation assays\",\n      \"pmids\": [\"37474739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate range of NIP45-directed SUMOylation beyond SLX4 incomplete\", \"How catenane recognition is achieved unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined the molecular scaffold underlying genome maintenance, showing NFATC2IP bridges SMC5/6 (via SLD1) and UBC9 (via SLD2) to position the UBC9-NSMCE2 E3 ligase.\",\n      \"evidence\": \"Genome-scale screen, knockout cells with bridge/micronuclei phenotypes, nascent-DNA association, reciprocal Co-IP, and AlphaFold-Multimer modeling\",\n      \"pmids\": [\"38503515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct enzymatic activation of NSMCE2 not biochemically reconstituted\", \"Physiological SUMO substrates at replication forks not enumerated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Documented a cardiac transcriptional role, showing NFATC2IP binds the β-MHC promoter to drive hypertrophy under miR-31-5p control.\",\n      \"evidence\": \"Luciferase reporter, ChIP-qPCR, miR-31-5p modulation, and AAC rat hypertrophy model\",\n      \"pmids\": [\"38894694\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether promoter binding is direct or NFAT-mediated unresolved\", \"Cofactor requirement at β-MHC promoter undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How NIP45's two functional regimes — NFAT-dependent transcriptional co-activation and SLD-mediated SUMO-pathway scaffolding — are partitioned across cell types and conditions remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model connecting transcriptional and genome-integrity roles\", \"Regulatory switch (localization, phosphorylation, partner availability) between the two functions unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 10]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [9, 10]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [5, 10]}\n    ],\n    \"complexes\": [\"SMC5/6\"],\n    \"partners\": [\"NFATC2\", \"MAF\", \"TRAF1\", \"TRAF2\", \"PRMT1\", \"UBC9\", \"SLX4\", \"TRAF6\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}